Three Charts That Will Change Your Mind About This Sector

Many investors think biotech is too risky. These three charts will make them change their minds...‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  [Wealthy Retirement]( SPONSORED [Networks Are Trying to BAN Bill O'Reilly's Money Message](  [Bill O'Reilly Video](  One network actually told us that it will NOT run Bill O'Reilly's wealth-building message because of its "conservative nature"! This is a conspiracy in plain sight. [Watch O'Reilly's money message NOW, before it gets pulled from the internet forever.](  Editor's Note: As Contributing Analyst Jody Chudley points out in today's article, when it comes to investing, sometimes it's important to check your assumptions at the door. Many investors think of the biotech sector as too risky. But it's safer than you may think... and more profitable. In fact, Chief Income Strategist Marc Lichtenfeld has just uncovered a way to [double your money 12 times over the next 12 months with biotech companies](. Sound too good to be true? [Wall Street has been using this same strategy for decades.]( And we all know it pays to follow the smart money. [>>Click here to watch Marc's presentation.]( - Rachel Gearhart, Associate Franchise Publisher  [MARKET TRENDS]( Three Charts That Will Change Your Mind About This Sector Jody Chudley, Contributing Analyst, The Oxford Club [Jody Chudley] I have enjoyed one enormous benefit from the COVID-19 outbreak... Because school has been canceled, my two daughters have been home every day since mid-March. Getting to spend time with them every single day is a blessing. They're 11 and 13 years old, and they still like hanging around with me. But I'm no fool... I'm very aware that the window of time where they still think I'm worth listening to is vanishing quickly. I'm determined to take advantage of every second that I have in which they still want to learn things it took me decades to figure out. One lesson that I want to teach my kids is that a willingness to admit you have made a mistake is a powerful asset. Far too many people (me included) cling to their opinions long after they have been proven wrong. This unwillingness to admit that you are wrong can cost you friends, time and - in the stock market - a lot of money. A mistaken belief that I have held on to for far too long is that putting money into the biotech sector is more like speculation than investing. I've seen the absurd returns that some biotech stocks have put up and wrongly assumed that the entire sector is too risky. And that assumption has cost me... The chart below compares the value of $10,000 invested in the iShares Nasdaq Biotechnology ETF (Nasdaq: IBB) at its inception in 2001 with $10,000 invested in the S&P 500 over the same period. [Chart - ]  Over this two-decade stretch (that is long term, folks), the biotech ETF has smashed the performance of the S&P 500. The $10,000 investment in biotech is now worth $42,690 versus $23,140 from the same amount invested in the S&P 500. I honestly had no idea that biotech had done this much better than the S&P 500 over this long of a time period. There is nothing risky about an entire sector that vastly outperforms. My ignoring of this sector is a mistake that has cost me a lot of money. Now I'm trying to learn from that mistake.  SPONSORED [Data Scientists of the World Will Be Baffled...]( [Staring at Holograph Screen](  The data scientists will no doubt throw up their hands today. Because in the last couple of days, one data scientist made [an earth-shattering discovery](. It will change everything we thought we knew about investing and saving for retirement. In fact, it could help speed up the growth of EVERY American's retirement plan by 10X. [Check out the BIG REVEAL right here.](   The Biotech Sector May Be Ready to Run Again Here is where the biotech sector gets even more interesting to me today... Despite having vastly outperformed over two decades, biotech has actually significantly underperformed over the past five years. To me, that smells like the sector might be ready to go on a tear. Since 2015, biotech stocks have been in a bit of a lull. While the S&P 500 has risen by 53.9% since 2015, biotech is up only 14.22%. Biotech stocks are still up but have vastly underperformed their historical performance. [Chart - ]  But now COVID-19 is changing the narrative around biotech stocks. Investor interest is quickly returning. Biotech has been leading the charge to find treatments for the virus. The virus has also led to the acceleration of the process by which new drugs are developed and approved. With more investors looking at biotech companies, they have been reminded that this is a very lucrative area to invest in. Unlike most businesses, which plod along slowly generating wealth, biotechs can create incredible value quickly with a successful treatment. With COVID-19 bringing all kinds of attention back to biotech, I believe the entire sector may be ready for a long stretch of outperformance. These stocks are like a coiled spring after their five-year lull. Supporting that view is the fact that the sector has broken out in 2020, now up 18% against a flat stock market. [Chart - ]  No question that the charts make the sector look interesting. So too does the fact that these companies are not in any way dependent on the performance of the economy. People still get sick - and not just from COVID-19 - so the idea of adding stocks that can outperform even if the economy stays in the doldrums is very appealing. I'm not too proud to admit that I was wrong about biotech. The sector could be a great "hedge" for portfolios against a prolonged coronavirus-created downturn. Good investing, Jody P.S. Biotech may be up for the year, but there are still plenty of ways to profit... You just need to [know where to look](. My colleague Marc Lichtenfeld recently put together a presentation on how to land profits in the biotech sector using the same [market "tell" that Wall Street has been using for decades](. [Check out his video presentation here.]( [Leave a Comment](  MORE FROM WEALTHY RETIREMENT [How to Profit From Wall Street's Top Catalysts](    [Are These All-American Dividends Safe?](    [Are You Playing Russian Roulette With Your Savings?](  [Facebook]( [Facebook]( [Twitter]( [Twitter]( [Email Share](mailto:?subject=A%20great%20piece%20from%20Wealthy%20Retirement...&body=From%20Wealthy%20Retirement:%0D%0A%0D%0A Many%20investors%20think%20biotech%20is%20too%20risky.%20These%20three%20charts%20will%20make%20them%20change%20their%20minds... %0D%0A%0Dshared) [Email Share](mailto:?subject=A%20great%20piece%20from%20Wealthy%20Retirement...&body=From%20Wealthy%20Retirement:%0D%0A%0D%0A Many%20investors%20think%20biotech%20is%20too%20risky.%20These%20three%20charts%20will%20make%20them%20change%20their%20minds... %0D%0A%0D  SPONSORED [Could One $7 Tech Stock Help "Resurrect" Your Investment Account?]( If you lost money in the markets in February and March... [THIS]( could be exactly what you've been looking for. This $7 stock has more than a hundred patents ... many big-name partnerships... a top-shelf management team... and a LONG history of quarterly revenue growth. [Get the details here...](  [The Oxford Club](  You are receiving this email because you subscribed to Wealthy Retirement. Wealthy Retirement is published by The Oxford Club. Questions? Check out our [FAQs](. Trying to reach us? [Contact us here.]( Please do not reply to this email as it goes to an unmonitored inbox. [Privacy Policy]( | [Whitelist Wealthy Retirement]( | [Unsubscribe]( © 2020 The Oxford Club, LLC All Rights Reserved The Oxford Club | [105 West Monument Street](#) | [Baltimore, MD 21201](#) North America: [1.800.589.3430](#) | International: [+1.443.353.4334](#) | Fax: [1.410.329.1923](#) [Oxfordclub.com](   The Oxford Club is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. Members should be aware that although our track record is highly rated by an independent analysis and has been legally reviewed, investment markets have inherent risks and there can be no guarantee of future profits. The stated returns may also include option trades. We expressly forbid our writers from having a financial interest in their own securities recommendations to readers. All of our employees and agents must wait 24 hours after online publication or 72 hours after the mailing of printed-only publications prior to following an initial recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, 105 W. Monument Street, Baltimore MD 21201.